The Dolphins began the season 4-20 (.167) against playoff teams. This season they’re 1-5 (.167) against playoff teams. In a sense, they’re still the same Dolphins.
– FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients – – FREEDOM2-DM1 5 mg/kg cohort on track to readout in Q1 2026, with all patients ...
BOISE, Idaho, Nov. 17, 2025 /PRNewswire/ - Perpetua Resources Corp. (Nasdaq: PPTA) (TSX: PPTA) ("Perpetua Resources" or "Perpetua" or the "Company") announced today that its unaudited condensed ...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for ...
FREDERICK, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...
Huntsman Cancer Institute at the University of Utah (the U) faculty and staff continue to set new standards in cancer research, clinical innovation, and community engagement. The faculty and staff’s ...
More than 250 local youth received mentorship, lessons on life, and wrestling instruction as beneficiaries of the Iron Mike Foundation. A Saturday, Dec. 6 collaboration between Trenton Wrestling Club ...
A man died this week after being hit by a vehicle near 21st and Woodlawn in northeast Wichita, highlighting ongoing safety ...
– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU ™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME program ...
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-reports-third-quarter-2025-financial-results-and-recent ...
The MarketWatch News Department was not involved in the creation of this content. US market introduction of the CNSide(R) CSF diagnostics platform, with first national coverage agreement with ...